Luqing Shang

938 total citations
27 papers, 691 citations indexed

About

Luqing Shang is a scholar working on Molecular Biology, Infectious Diseases and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Luqing Shang has authored 27 papers receiving a total of 691 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 10 papers in Infectious Diseases and 9 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Luqing Shang's work include Viral Infections and Immunology Research (9 papers), RNA and protein synthesis mechanisms (7 papers) and Computational Drug Discovery Methods (4 papers). Luqing Shang is often cited by papers focused on Viral Infections and Immunology Research (9 papers), RNA and protein synthesis mechanisms (7 papers) and Computational Drug Discovery Methods (4 papers). Luqing Shang collaborates with scholars based in China, United States and Japan. Luqing Shang's co-authors include Zheng Yin, Mengying Xu, Zheng Yin, Yaxin Wang, Linfeng Li, Wei Zhao, Yuying Ma, Shuai He, Yangyang Zhai and Subhash G. Vasudevan and has published in prestigious journals such as PLoS ONE, ACS Catalysis and ACS Applied Materials & Interfaces.

In The Last Decade

Luqing Shang

27 papers receiving 680 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luqing Shang China 15 322 207 187 119 116 27 691
Marcella Bassetto United Kingdom 19 272 0.8× 222 1.1× 65 0.3× 65 0.5× 435 3.8× 54 1.0k
Elumalai Pavadai United States 14 261 0.8× 97 0.5× 143 0.8× 96 0.8× 74 0.6× 35 508
Carina Stiller Germany 6 232 0.7× 363 1.8× 47 0.3× 119 1.0× 43 0.4× 9 643
Jyh‐Haur Chern Taiwan 18 318 1.0× 311 1.5× 344 1.8× 63 0.5× 291 2.5× 29 1.0k
Karine Barral France 13 429 1.3× 377 1.8× 27 0.1× 131 1.1× 428 3.7× 24 1.2k
Leentje Persoons Belgium 15 280 0.9× 178 0.9× 20 0.1× 56 0.5× 323 2.8× 66 793
A. Peter Johnson United Kingdom 17 453 1.4× 193 0.9× 27 0.1× 95 0.8× 194 1.7× 40 798
Nadine H. Elowe Canada 13 467 1.5× 150 0.7× 21 0.1× 124 1.0× 66 0.6× 18 743
Kristina Lanko Netherlands 9 216 0.7× 300 1.4× 63 0.3× 233 2.0× 133 1.1× 14 589
Evelien Vanderlinden Belgium 19 400 1.2× 210 1.0× 83 0.4× 35 0.3× 285 2.5× 35 996

Countries citing papers authored by Luqing Shang

Since Specialization
Citations

This map shows the geographic impact of Luqing Shang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luqing Shang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luqing Shang more than expected).

Fields of papers citing papers by Luqing Shang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luqing Shang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luqing Shang. The network helps show where Luqing Shang may publish in the future.

Co-authorship network of co-authors of Luqing Shang

This figure shows the co-authorship network connecting the top 25 collaborators of Luqing Shang. A scholar is included among the top collaborators of Luqing Shang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luqing Shang. Luqing Shang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Yaxin, Binghong Xu, Hao Wang, et al.. (2022). Discovery of SARS-CoV-2 3CLPro Peptidomimetic Inhibitors through the Catalytic Dyad Histidine-Specific Protein–Ligand Interactions. International Journal of Molecular Sciences. 23(4). 2392–2392. 8 indexed citations
3.
Zhuo, Linsheng, Mingshu Wang, Jing‐Fang Yang, et al.. (2021). Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology. Topics in Current Chemistry. 379(3). 23–23. 8 indexed citations
4.
Xu, Binghong, et al.. (2021). Reversible covalent inhibitors suppress enterovirus 71 infection by targeting the 3C protease. Antiviral Research. 192. 105102–105102. 14 indexed citations
5.
Qiao, Dan, Xiao Liang, Lu Zhang, et al.. (2020). Establishment of a Customizable Fluorescent Probe Platform for the Organelle-Targeted Bioactive Species Detection. ACS Sensors. 5(7). 2247–2254. 18 indexed citations
6.
Zhao, Xiujie, Zhiwen Fan, Yanqi Qiao, et al.. (2020). AIEgens Conjugation Improves the Photothermal Efficacy and Near-Infrared Imaging of Heptamethine Cyanine IR-780. ACS Applied Materials & Interfaces. 12(14). 16114–16124. 60 indexed citations
7.
Ma, Yuying, Linfeng Li, Shuai He, et al.. (2019). Application of Dually Activated Michael Acceptor to the Rational Design of Reversible Covalent Inhibitor for Enterovirus 71 3C Protease. Journal of Medicinal Chemistry. 62(13). 6146–6162. 26 indexed citations
8.
Wang, Yaxin, Lin Cao, Yangyang Zhai, et al.. (2017). Inhibition of enterovirus 71 replication by an α-hydroxy-nitrile derivative NK-1.9k. Antiviral Research. 141. 91–100. 11 indexed citations
9.
Wang, Yaxin, Lin Cao, Yangyang Zhai, et al.. (2017). Structure of the Enterovirus 71 3C Protease in Complex with NK-1.8k and Indications for the Development of Antienterovirus Protease Inhibitor. Antimicrobial Agents and Chemotherapy. 61(7). 14 indexed citations
10.
Ma, Yuying, et al.. (2016). Synthesis and structure–activity relationship of α-keto amides as enterovirus 71 3C protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 26(7). 1762–1766. 20 indexed citations
11.
Han, Zhiqiang, Xiao Liang, Yaxin Wang, et al.. (2016). The discovery of indole derivatives as novel hepatitis C virus inhibitors. European Journal of Medicinal Chemistry. 116. 147–155. 16 indexed citations
12.
Zhang, Rui, et al.. (2016). Discovery of 2′-α-C-Methyl-2′-β-C-fluorouridine Phosphoramidate Prodrugs as Inhibitors of Hepatitis C Virus. ACS Medicinal Chemistry Letters. 7(12). 1197–1201. 11 indexed citations
13.
Shang, Luqing, Kai Lin, & Zheng Yin. (2014). Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design. Current Pharmaceutical Design. 20(5). 694–703. 6 indexed citations
14.
15.
Shang, Luqing, Shumei Zhang, Xi Yang, et al.. (2014). Biochemical Characterization of Recombinant Enterovirus 71 3C Protease with Fluorogenic Model Peptide Substrates and Development of a Biochemical Assay. Antimicrobial Agents and Chemotherapy. 59(4). 1827–1836. 20 indexed citations
16.
Shang, Luqing, Mengying Xu, & Zheng Yin. (2012). Antiviral drug discovery for the treatment of enterovirus 71 infections. Antiviral Research. 97(2). 183–194. 93 indexed citations
17.
Schüller, Andreas, Zheng Yin, C. S. Brian Chia, et al.. (2011). Tripeptide inhibitors of dengue and West Nile virus NS2B–NS3 protease. Antiviral Research. 92(1). 96–101. 79 indexed citations
18.
Wang, Qiang, Fuming Xu, Jian Zhang, et al.. (2010). Design, Synthesis and Preliminary Activity Evaluation of Novel L-Lysine Derivatives as Aminopeptidase N/CD13 Inhibitors. Protein and Peptide Letters. 17(7). 847–853. 3 indexed citations
19.
Shang, Luqing, Hao Fang, Huawei Zhu, et al.. (2009). Design, synthesis and SAR studies of tripeptide analogs with the scaffold 3-phenylpropane-1,2-diamine as aminopeptidase N/CD13 inhibitors. Bioorganic & Medicinal Chemistry. 17(7). 2775–2784. 12 indexed citations
20.
Shang, Luqing, Qiang Wang, Hao Fang, et al.. (2008). Novel 3-phenylpropane-1,2-diamine derivates as inhibitors of aminopeptidase N (APN). Bioorganic & Medicinal Chemistry. 16(23). 9984–9990. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marcella Bassetto Breakdown of academic impact, for papers by Elumalai Pavadai Breakdown of academic impact, for papers by Carina Stiller Breakdown of academic impact, for papers by Jyh‐Haur Chern Breakdown of academic impact, for papers by Karine Barral Breakdown of academic impact, for papers by Leentje Persoons Breakdown of academic impact, for papers by A. Peter Johnson Breakdown of academic impact, for papers by Nadine H. Elowe Breakdown of academic impact, for papers by Kristina Lanko Breakdown of academic impact, for papers by Evelien Vanderlinden
Rankless by CCL
2026